Technology
Health
Biotechnology

Alkermes

$35.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market

Why Robinhood?

You can buy or sell Alkermes and other stocks, options, ETFs, and crypto commission-free!

About

Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. Read More The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Employees
2,300
Headquarters
Dublin, Dublin
Founded
2011
Market Cap
5.45B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
869.14K
High Today
$35.35
Low Today
$34.83
Open Price
$35.00
Volume
370.80K
52 Week High
$61.21
52 Week Low
$27.54

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Pharmaceutical
Europe (Non-UK)
Europe

News

StreetInsiderMar 6

UPDATE: Urovant Sciences (UROV) Appoints James Robinson to Board

(Updated - March 6, 2019 8:02 AM EST) Urovant Sciences (NASDAQ: UROV) today announced James Robinson, President and Chief Operating Officer of Alkermes, will join its Board of Directors. “Jim’s extensive leadership, knowledge and experience in the biopharmaceutical space combined with his unique understanding of the urology market will help inform Urovant’s strategies and growth opportunities,” said Keith A. Katkin, Chief Executive Officer of Urovant. “Urovant is pleased to welcome him to our board and my...

37
PR NewswireMar 5

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

DUBLIN, March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39th Annual Health Care Conference on Tuesday, Mar.

10
Yahoo FinanceFeb 28

Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunoco LP (SUN), Citrix Systems, Inc. (CTXS), Alkermes plc (ALKS), CubeSmart (CUBE), Morningstar, Inc. (MORN), and Synopsys, Inc. (SNPS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. Complimentary Access: Research Re...

17

Earnings

-$0.09
$0.05
$0.20
$0.34
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.